Article Text

Download PDFPDF
Successful treatment of empyema thoracis with human recombinant deoxyribonuclease
  1. G Simpson1,2,
  2. D Roomes1,
  3. B Reeves1
  1. 1Department of Thoracic Medicine, Cairns Base Hospital, Cairns, Queensland, Australia
  2. 2Adjunct Associate Professor, James Cook University
  1. Correspondence to:
    Dr G Simpson, 130 Abbott Street, Cairns, Queensland 4870, Australia;
    marjo{at}iig.com.au

Abstract

Fibrinolytic enzymes, particularly streptokinase, are now widely used to treat empyema thoracis. Recent in vitro evidence suggests that streptokinase has no effect on pus viscosity but that deoxyribonuclease (DNase) reduces the viscosity of pus. We report the first use of human recombinant DNase given intrapleurally to treat an empyema which had not resolved after standard treatment with streptokinase.

  • empyema thoracis
  • deoxyribonuclease
  • streptokinase

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • The authors received no financial support for this study.